Acute cardiac care & resuscitation
Novel Role for Cardiolipin as a Target of Therapy to Mitigate Myocardial Injury Caused by Venoarterial Extracorporeal Membrane Oxygenation
Authors' conclusion
We identified a novel mechanism by which VA-ECMO promotes myocardial injury and further identify cardiolipin as an important target of therapy to reduce infarct size and to preserve mitochondrial function in the setting of VA-ECMO for acute myocardial infarction.
Study context
- Population
- Human subjects with HF before heart transplantation; healthy and adult swine with acute MI (LAD occlusion/reperfusion)
- Comparison
- Venoarterial extracorporeal membrane oxygenation (VA-ECMO) vs reperfusion alone, with and without MTP-131
- Outcome
- Infarct size
Methodological detailshuman LV tissue and swine models, closed-chest ischemia/reperfusion swine model
- Human LV tissue and swine models
- Closed-chest ischemia/reperfusion swine model
Main finding
As reported in the abstract
VA-ECMO vs Reperfusion alone: P < 0.001 · MTP-131 + VA-ECMO vs Reperfusion alone: P = 0.03 · MTP-131 + VA-ECMO vs VA-ECMO: P < 0.001
Further findings
LV cardiolipin and tafazzin in humans before heart transplantation
- Significantly reduced with VA-ECMO vs without VA-ECMO
LV cardiolipin and tafazzin in healthy swine · 6 hours of VA-ECMO
- Decreased with VA-ECMO vs sham controls
Mitochondrial and oxidative effects in ischemia/reperfusion swine
- VA-ECMO decreased cardiolipin and tafazzin, disrupted mitochondrial integrity, reduced electron transport chain (ETC) function, promoted oxidative stress
- MTP-131 restored cardiolipin and tafazzin, stabilized mitochondrial function, reduced oxidative stress in LV
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →